A new study in the Journal of Leukocyte Biology has found that B cells promote inflammation and bone loss in type 2 diabetes-associated periodontal disease patients. If the B cells can be treated properly, the resulting effect may be a proactive result in periodontal disease.
"Our study identified common inflammatory mechanisms shared by type 2 diabetes and periodontal disease. It paves the way for the development of novel therapeutics which aim to simultaneously treat both type 2 diabetes and its complications," said Min Zhu, Ph.D., a researcher involved in the work from the Boston University School of Medicine.
Scientists used 2 groups of mice, 1 with a genetic alternation that eliminated all B cells and another with normal B cell levels. According to a Medical News Today article, ?When fed a low-fat diet, without development of obesity and type 2 diabetes, both groups demonstrated a similar extent of oral bone loss and inflammation. However, when they were fed a high-fat diet, became obese and developed type 2 diabetes, oral bone loss and inflammation occurred in the normal group with B cells, but did not develop in the group with the altered gene to knock out the B cells.?
?B cell targeting drugs are available for B cell cancers and these new findings could open the door for applying new B cell-based treatment strategies for periodontal diseases and perhaps other inflammatory conditions," said John Wherry, Ph.D., Deputy Editor of the Journal of Leukocyte Biology.